Eisai Inc - Strategic SWOT Analysis Review

Eisai Inc - Strategic SWOT Analysis Review
- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

ScopeBusiness description – A detailed description of the company’s operations and business divisions.Corporate strategy – GlobalData’s summarization of the company’s business strategy.SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.Company history – Progression of key events associated with the company.Major products and services – A list of major products, services and brands of the company.Key competitors – A list of key competitors to the company.Key employees – A list of the key executives of the company.Executive biographies – A brief summary of the executives’ employment history.Key operational heads – A list of personnel heading key departments/functions.Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.Highlights

Eisai Inc (Eisai America), a subsidiary of Eisai Co Ltd, is a healthcare company that discovers, develops, and markets pharmaceutical products. The company's major products include Aricept for Alzheimer’s treatment, Banzel for adjunctive treatment, and Dayvigo for the insomnia. The company’s research and development activities focus on therapeutic areas such as neuroscience; cancer, antibody-based programs; vascular, inflammatory, and immunological reaction. Eisai America established partnerships and collaborations with global companies such as Pfizer, Janssen Pharmaceutica Inc, Elan Pharma International Ltd, and Elan Pharmaceutical Inc for the development and distribution of drugs. Eisai America is headquartered in New Jersey, the US.

Eisai Inc Key Recent Developments

Apr 11,2023: Eisai and patient advocacy partners launch Made of More - An education initiative to spotlight head and neck cancer
Aug 18,2022: Eisai reinforces commitment to collaboration and innovation to support patients and communities through new U.S. headquarters
Jun 02,2022: Eisai to Present Latest Data on Lemborexant at the 36th Annual Sleep 2022 Meeting
Mar 15,2022: Biogen and Eisai revise agreements on Alzheimer’s disease therapies

Reasons to BuyGain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.Note:Some sections may be missing if data is unavailable for the company.